Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Peringkat dalam Saham #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Harga Saham
$8.46
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$514.33M
Perubahan (1 hari)
-2.08%
Perubahan (1 tahun)
128.03%
Negara
US
Perdagangan Kyverna Therapeutics, Inc. (KYTX)

Kategori

Riwayat pemecahan saham untuk Kyverna Therapeutics, Inc. (KYTX)
Saham Kyverna Therapeutics, Inc. (simbol: KYTX) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Aug 31, 2026.
Satu lembar saham KYTX yang dibeli sebelum Aug 31, 2026 sekarang setara dengan 0 lembar saham KYTX.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH